Search results
Sarepta’s Elevidys secures US label expansion for DMD
Pharmaceutical Technology via Yahoo Finance· 13 hours agoCell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content...
Another Study Finds CRISPR Gene Therapy Fights Sickle Cell | Fox 11 Tri Cities Fox 41 Yakima
FOX 11/41 Yakima· 4 days ago“It’s encouraging that this gene-editing treatment continues to show promising efficacy for sickle...
Novel gene-editing therapy continues to show positive results in sickle cell patients
Medical Xpress· 7 days agoConducted as part of the multicenter RUBY Trial, researchers shared data on the safety and...
Gene editing technology is revolutionizing disease treatment | The Excerpt
USA Today· 1 day agoOn a special episode (first released on June 20, 2024) of The Excerpt podcast: With the advent of...
Sarepta Stock Surges On FDA News; Industrial Stock In Buy Zone
Investor's Business Daily· 14 hours agoIndustrial stock Honeywell International got a boost on acquisition news as it sits in a buy zone,...
Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost
InvestorPlace· 17 hours agoSarepta Therapeutics (NASDAQ:SRPT) stock jumped about 30% overnight after the Food and Drug...
Investigative Sickle Cell gene therapy patient advocates for change on Capitol Hill
FOX 8 Cleveland· 1 day ago22-year-old Canaan Evans has been living with Sickle Cell disease his entire life, but thanks to a...
6 Ways To Engineer Adenoviruses For Gene Therapy And Vaccines
Forbes· 3 days agoSince their discovery in the 1950s, adenoviruses have been increasingly recognized as versatile and...
Decades of gene therapy research pay off big for Madison company
Wisconsin State Journal· 2 days ago“From the very start, we wanted to focus on gene therapy,” said Jim Hagstrom, a molecular biologist...
Taysha Gene Therapies (NASDAQ:TSHA) Given Overweight Rating at Cantor Fitzgerald
ETF DAILY NEWS· 2 days agoTaysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a report released on Thursday ...